VIR BIOTECHNOLOGY ANNOUNCES PRIMARY ENDPOINT MET IN PIVOTAL PHASE 3 ECLIPSE 1 TRIAL FOR ELEBSIRAN AND TOBEVIBART IN CHRONIC HEPATITIS DELTA

Reuters · 1d ago

Please log in to view news